Vnitřní lékařství 3/2020

DIFERENCIÁLNĚ-DIAGNOSTICKÉ OKÉNKO ANEB NA CO SE VÁS MOHOU ZEPTAT U ATESTACE Hepatorenální syndrom – update 2020 E62 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2020; 66(3): e58–e62 /  www.casopisvnitrnilekarstvi.cz LITERATURA 1. Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015; 62: 986–994. 2. Huelin P, Piano S, Solà E et al. Validation of a staging system for acute kidney injury in patients with cirrhosis and association with acute‑on‑chronic‑liver failure. Clin Gastroen- terol Hepatol 2017; 15: 438–445. 3. Davenport A, Sheikh MF, Lamb E, et al. Acute kidney injury in acute‑on chronic liver failure: where does hepatorenal syndrome fit? Kidney International 2017; 92: 1058–1070. 4. Solé C, Pole E, Solà E, et al. Hepatorenal syndrome in the era of acute kidney injury. Li- ver International 2018; 25: 1–11. 5. Belcher JM, Garcia‑Tsao G, Sanyal AJ, et al. Association of AKI with mortality and compli- cations in hospitalized patients with cirrhosis. Hepatology 2013; 57: 753–762. 6. Fagundes C, Barreto R, Guevara M, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepa- tol 2013; 59: 474–481. 7. Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepato- renal syndrome. Gastroenterology Report 2017; 5: 127–137. 8. Krones E, Fickert P, Zitta S, et al. The chronic kidney disease epidemiology collobora- tion equation combining creatinine and cystatin C accurately assesses renal function in patients with cirrhosis. BMC Nephrol 2015; 16: 1–10. 9. BarretoR,EliaC,SolàE,etal.Urinaryneutrophilgelatinase‑associated lipocalinpredictskidney outcomeanddeath inpatientswithcirrhosisandbacterial infections.JHepatol2014;61:35–42. 10. Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 2013; 57: 1–37. 11. Sola E, Kerbert AJ, Verspaget HW, et al. Plasma copeptin as biomarker of disease pro- gression and prognosis in cirrhosis. J Hepatol 2016; 65: 914–920. 12. Kerbert AJ, Verbeke L, Chiang FW, et al. Copeptin as an Indicator of Hemodynamic De- rangement and Prognosis in Liver Cirrhosis. PloS One 2015; 10: e0138264. 13. Adebayo D, Morabito V, Davenport A, et al. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int 2015; 87: 509–515. 14. Mandorfer M, Bota S, Schwabl P, et al. Nonselective beta blockers increase risk for he- patorenal syndrome and death in patients with cirrhosis and spontaneous bacterial pe- ritonitis. Gastroenterology 2014; 146: 1680–1690. 15. Theocharidou E, Krag A, Bendtsen F, et al. Cardiac dysfunction in cirrhosis – does adre- nal function play a role? A hypothesis. Liver Int 2012; 32: 1327–1332. 16. Weichselbaum L, Gustot T. The Organs in Acute‑on‑Chronic Liver Failure. Semin Li- ver Dis 2016; 36: 174–180. 17. Shah N, Mohamed PE, Jover‑cobos M et al. Increased renal expression and urina- ry excretion of TLR4 in acute kidney injury associated with cirrhosis. Liver Int 2013; 33: 398–409. 18. GustotT,DurandF,LebrecD,etal.Severesepsis incirrhosis.Hepatology2009;50:2022–2033. 19. Bernardi M, Caraceni P, Navickis RJ, et al. Albumin infusion in patients undergo- ing large‑volume paracentesis: a meta‑analysis of randomized trials. Hepatology 2012; 55: 1172–1181. 20. European Association for the Study of the Liver. EASL Clinical Practice Guideli- nes for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69: 406–460. 21. Bernardi M, Ricci CS, Zaccherini G. Role of human albumin in the management of com- plications of liver cirrhosis. J Clin Exp Hepatol 2014; 4: 302–311. 22. Afinogenova Y, Tapper EB. The efficacy and safety profile of albumin administration for patients with cirrhosis at high risk of hepatorenal syndrome is dose dependent. Gas- troenterol Rep (Oxf) 2015; 3: 216–221. 23. Salerno F. Albumin treatment regimen for type 1 hepatorenal syndrome: a dose­ ‑response meta‑analysis. BMC Gastroenterol 2015; 55: 1–11. 24. Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous in- fusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomi- zed controlled study. Hepatology 2016; 63: 983–992. 25. Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of he- patorenal syndrome: a randomized study. J Hepatol 2012; 56: 1293–1298. 26. Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology 2015; 62: 567–574. 27. European Association for the Study of the Liver. EASL clinical practise guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndro- me in cirrhosis. J Hepatol 2010; 53: 397–417.